Lynx1 Capital Management LP
DORADO, PR · CIK 1910456 · 13F filing filed 2023-08-14
SEC-registered investment adviser since 2023 · limited partnership
- Assets managed$626.7m
- Staff5 · 4 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds2 (1 hedge) · $576.8m gross assets
- Form ADV · 2026-03-31SEC adviser record
- Legal entityLYNX1 CAPITAL MANAGEMENT LP (US)
- Kindhedge funds, private equity, futures
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 1
This report includes the holdings of 1 other manager that shares the investment decisions:
- Lynx1 Capital Advisors LLC – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2023
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| MERUS N V MRUS | $30.3m19.88% | Added +84.8k |
| CABALETTA BIO INC CABA | $28.2m18.45% | Reduced -273.2k |
| ALPINE IMMUNE SCIENCES INC NVLS | $27.5m17.99% | Reduced -465.7k |
| CYMABAY THERAPEUTICS INC CBAY | $13.2m8.65% | Reduced -164.9k |
| TSCAN THERAPEUTICS INC TCRX | $13.1m8.56% | New |
| GH RESEARCH PLC GHRS | $11.5m7.54% | New |
| PARDES BIOSCIENCES INC COM | $7.1m4.63% | Added +578.4k |
| THESEUS PHARMACEUTICALS INC COM | $7.1m4.63% | Reduced -4.2k |
| KINNATE BIOPHARMA INC KNTE | $6.2m4.07% | Reduced -165.5k |
| NEOLEUKIN THERAPEUTICS INC COM | $2.6m1.68% | Added +666.2k |
| PIERIS PHARMACEUTICALS INC COM | $1.6m1.06% | Added +2.7m |
| CULLINAN THERAPEUTICS INC CGEM | $1.2m0.81% | New |
| PASSAGE BIO INC COM | $1.1m0.72% | Reduced -2.2m |
| STRUCTURE THERAPEUTICS INC GPCR | $956.1k0.63% | Unchanged |
| ATHIRA PHARMA INC COM | $571.0k0.37% | New |
| PHARVARIS N V PHVS | $321.3k0.21% | Reduced -5.0k |
| COMPASS PATHWAYS PLC CMPS | $166.5k0.11% | New |
| DBV TECHNOLOGIES S A SPONSORED ADR | $34.7k0.02% | New |
Sold out since Q1 2023
| Security | Value then |
|---|---|
| BELLUS HEALTH INC NEW BLU | $6.2m866.6k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| PASSAGE BIO INC 13D · filed 2026-07-02 | 21.0% |
| GH RESEARCH PLC GHRS · 13G · filed 2026-08-14 | 19.3%≈ $354.0m |
| NEUPHORIA THERAPEUTICS INC NEUP · 13D · filed 2025-12-29 | 16.3%≈ $3.8m |
| TSCAN THERAPEUTICS INC TCRX · 13G · filed 2026-08-14 | 13.1%≈ $20.1m |
| KORRO BIO INC KRRO · 13G · filed 2026-04-02 | 10.7%≈ $20.3m |
| C4 THERAPEUTICS INC CCCC · 13G · filed 2026-08-14 | 10.0%≈ $63.1m |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2025-11-14 | 9.8%≈ $105.0m |
| STOKE THERAPEUTICS INC STOK · 13G · filed 2026-08-14 | 6.5%≈ $132.1m |
| IBIO INC IBIO · 13G · filed 2026-08-14 | 5.4%≈ $4.9m |
| PRECISION BIOSCIENCES INC DTIL · 13G · filed 2026-07-20 | 5.4%≈ $10.9m |
| AGIOS PHARMACEUTICALS INC AGIO · 13G · filed 2026-05-06 | 5.1%≈ $111.8m |
Trades reported as a company insider in Q2 2023
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2023-05-31 | TSCAN THERAPEUTICS INC 10% owner · See footnote | Sold | $63.9k25.4k shares |